Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | PNP | P00491 | 7/20 | 0.71 |
| ▸ | HBB | P68871 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | USP2 | O75604 | 1/20 | 0.71 |
| ▸ | EDNRA | P25101 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | HPRT1 | P00492 | 5/20 | 0.65 |
| ▸ | POLG | P54098 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | VCP | P55072 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14501075 | 0.90 | PNP (0.73) | MEN1KMT2APNPHBBTSHR | |
| SCHEMBL14501172 | 0.90 | PNP (0.73) | MEN1KMT2APNPHBBTSHR | |
| SCHEMBL9019935 | 0.90 | MEN1 (0.68) | MEN1KMT2APNPHBBTSHR | |
| SCHEMBL12088904 | 0.89 | PNP (0.71) | MEN1KMT2APNPHBBTSHR | |
| Glycyl Ester Of Acyclovir SCHEMBL10502091 | 0.89 | PNP (0.71) | MEN1KMT2APNPHBBTSHR | |
| SCHEMBL7814355 | 0.89 | MEN1 (0.76) | MEN1KMT2APNPHBBTSHR | |
| SCHEMBL12671989 | 0.88 | MEN1 (0.66) | MEN1KMT2APNPHBBTSHR | |
| SCHEMBL14501071 | 0.88 | MEN1 (0.68) | MEN1KMT2APNPHBBTSHR | |
| SCHEMBL14421640 | 0.87 | PNP (0.74) | MEN1KMT2APNPHBBTSHR | |
| SCHEMBL8842958 | 0.87 | PNP (0.69) | MEN1KMT2APNPHBBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4294831-A | ANTIVIRAL ACTIVITY | BURROUGHS WELLCOME CO. (US) | 1981-10-13 | — | — | US | claimed |
| US-8278264-B2 | Compositions and methods for enhancing drug delivery across and into ocular tissues | KAI PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120225826-A1 | Transporters Comprising Spaced Arginine Moieties | The Board of Trustees of the Leland Stanford Junior University; and Cellgate, Inc. | 2012-09-06 | — | — | US | disclosed |
| US-20110206610-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | KAI PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20100081618-A1 | Transporters Comprising Spaced Arginine Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| US-7585834-B2 | Transporters comprising spaced arginine moieties | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-09-08 | — | — | US | disclosed |
| EP-0704445-B1 | Preparation of N-9 substituted guanine compounds | HOFFMANN LA ROCHE (CH) | 1999-04-21 | — | — | EP | disclosed |
| US-5565565-A | Preparation of N-9 substituted guanine compounds | SYNTEX (U.S.A.) INC. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0704445-A1 | Preparation of N-9 substituted guanine compounds | F. Hoffmann-La Roche AG (CH) | 1996-04-03 | — | — | EP | disclosed |
| US-4360522-A | VIRICIDES | BURROUGHS WELLCOME CO. (US) | 1982-11-23 | — | — | US | disclosed |
| US-4323573-A | VIRICIDES | BURROUGHS WELLCOME CO. (US) | 1982-04-06 | — | — | US | disclosed |
| US-4294831-A | ANTIVIRAL ACTIVITY | BURROUGHS WELLCOME CO. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4287188-A | PARTICULARLY 9-(2-HYDROXYETHOXYMETHYL) GUANINE MONOPHOSPHATE AND SALTS, USEFUL AS ANTIVIRIAL AGENTS | BURROUGHS WELLCOME CO. (US) | 1981-09-01 | — | — | US | disclosed |
| US-4146715-A | ANTIVIRAL AGENTS | BURROUGHS WELLCOME CO. (US) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081618-A1 | Transporters Comprising Spaced Arginine Moieties | SLC43A1, SLC1A5, SLC7A5 | MEN1 2628/4885KMT2A 3052/4885PNP 348/4885 |
| US-20120225826-A1 | Transporters Comprising Spaced Arginine Moieties | SLC43A1, SLC1A5, SLC7A5 | MEN1 2628/4885KMT2A 3052/4885PNP 348/4885 |
| US-20110206610-A1 | COMPOSITIONS AND METHODS FOR ENHANCING DRUG DELIVERY ACROSS AND INTO EPITHELIAL TISSUES | SLC7A1, ADM2, ARG1 | MEN1 1162/4885KMT2A 3370/4885PNP 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.